)

Acumen Pharmaceuticals (ABOS) investor relations material
Acumen Pharmaceuticals Cantor Global Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Company and scientific background
Sabirnetug is a humanized monoclonal antibody with high selectivity for toxic amyloid-beta oligomers, originating from academic research and later reacquired from Merck as a wholly owned asset.
The oligomer hypothesis posits that soluble amyloid-beta aggregates are the primary neurotoxic species in Alzheimer's, disrupting synaptic function and linking A-beta to tau pathology.
Sabirnetug demonstrates 10,000-fold selectivity for oligomers over monomers and 90-fold over plaques, aiming to minimize target distraction and maximize efficacy.
Decades of research support the toxicity of oligomers, and sabirnetug targets a broad spectrum of these aggregates, potentially offering a differentiated therapeutic effect.
Monoclonal antibody specificity is crucial, and sabirnetug’s mechanism is designed to impact synaptic plasticity and cortical function by targeting oligomers.
Clinical development and trial data
Phase 1b INTERCEPT-AD trial in early Alzheimer's patients showed sabirnetug was well tolerated, with a 10% ARIA rate across dose groups, and consistent pharmacokinetics for monthly dosing.
PET imaging revealed a 20% reduction in amyloid plaque at the highest dose, and biomarker analysis indicated reversal of disease-related markers, supporting the drug’s mechanism.
Target engagement was confirmed using a novel ELISA-based assay, with maximal engagement at 25 and 60 mg/kg doses.
Lower ARIA rates compared to other antibodies may be due to IgG2 isotype and higher selectivity for oligomers over plaques.
No direct correlation was observed between plaque reduction and ARIA, highlighting the complexity of the underlying biology.
Phase 2 ALTITUDE-AD study and trial design
Phase 2 ALTITUDE-AD is an 18-month, well-powered study in early Alzheimer's, using 35 and 50 mg/kg IV doses every four weeks, with IDRS as the primary outcome.
Enrollment completed with 532 subjects in 10 months across the US, Canada, Germany, and Spain, reflecting strong interest and efficient execution.
The cohort is similar to those in other major trials, and the IDRS scale was strategically chosen for its sensitivity in early AD.
Dose modeling supports adequate target coverage at both dose levels, with expectations for differentiated ARIA rates between cohorts.
A two-step screening process using plasma pTau217 biomarker improved efficiency, reducing amyloid-negative screen failures and streamlining enrollment.
Next Acumen Pharmaceuticals earnings date

Next Acumen Pharmaceuticals earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage